Jerry McLaughlin, Chief Executive Officer and Director
Jerry McLaughlin has served as Chief Executive Officer and a member of the Board of Directors since June 2018. Prior to joining Neos, Mr. McLaughlin served as President and Chief Executive Officer of CNS biopharmaceutical company, AgeneBio, since June 2014. Prior to joining AgeneBio, he served as the Senior Vice President and Chief Commercial Officer of NuPathe Inc. until the company was acquired by Teva Pharmaceuticals Industries Ltd. in 2014. Previously, Mr. McLaughlin was at Endo Pharmaceuticals from 2001 to 2007 and served in a variety of commercial leadership roles at Merck from 1990 to 2001. He holds a B.A. in Economics from Dickinson College and an M.B.A. from Villanova University.
Richard Eisenstadt, Chief Financial Officer
Richard Eisenstadt has served as our Chief Financial Officer since May 2014. Prior to joining us, he served as Chief Financial Officer of ArborGen Inc. from June 2013 to May 2014, and as Vice President of Finance and Chief Financial Officer of Tranzyme, Inc. now Ocera Therapeutics, Inc. (NASDAQ: OCRX) from June 2003 to December 2012. He previously held financial leadership positions at Cogent Neuroscience, Inc. and Nimbus CD International, Inc. Mr. Eisenstadt received his M.B.A. from James Madison University and his B.A. in Economics from the University of North Carolina, Chapel Hill.
Dorothy Engelking, Vice President of Regulatory Affairs
Dorothy Engelking has served as our Vice President of Regulatory Affairs since April 2010. Prior to joining us, Ms. Engelking served as Vice President of Kendle International, Inc. from July 2008 to July2009, Senior Vice President of Regulatory Affairs at Xanodyne Pharmaceutics, Inc. from March 2006 to July 2008, and as Vice President of Regulatory Affairs at Watson Pharmaceuticals Inc., now Actavis plc (NYSE: ACT) from January 1999 to March 2006. She received her B.S. in Chemistry and M.S. in Analytical Chemistry from South Dakota School of Mines and Technology, and holds a Regulatory Certificate from the Regulatory Affairs Professional Society.
Russ McMahen, Senior Vice President of Research & Development
Russ McMahen has 25 years of industry experience specializing in solids, liquids and suspensions. Mr. McMahen oversees the development of new products and technology. He is the co-inventor of DTRS®, RDIM™, DVR™, DKP™, DPD™ and SLIC™ delivery technologies. At Neos, Mr. McMahen has held various positions including Senior Vice President, Research & Development, Executive Vice President of Operations and Vice President of Scientific Affairs. Prior to joining Neos, Mr. McMahen served at Zenith/Goldline Laboratories which was subsequently acquired by Ivax Pharmaceuticals. He has a Bachelor of Science degree in Chemical Engineering from Louisiana Tech University.
Margaret Cabano, Vice President of Operations
Margaret Cabano has 15 years of industry experience and leads all aspects of operations, supply chain and production including responsibilities for customer management, planning and project management. Prior to joining Neos, Ms. Cabano worked in operations and supply chain management for Adams Respiratory Therapeutics and Cardinal Health. Ms. Cabano holds an MBA in Operations Management Science and a Bachelor of Science in Supply Chain Logistics from the University of North Texas.
Asif Mughal, Vice President of Quality Assurance
Asif Mughal has over 15 years of experience of increasing responsibility in QC/QA management and leadership. In his last two assignments for West-Ward Pharmaceuticals and EMD Chemicals (an affiliate of Merck), Mr. Mughal had international and domestic quality system responsibility. Mr. Mughal earned his Bachelor Degree in chemistry from Temple University.
Steven Lutz, Vice President of Trade Sales
Steven has served as our Vice President of Sales since August 2014. He previously served as a consultant for us from April 2014 to June 2014. Previously, Mr. Lutz served as the President and Chief Executive Officer of Praelia Pharmaceuticals, Inc. from October 2011 to March 2014. Mr. Lutz was a founder of Cornerstone Therapeutics, Inc., which was subsequently acquired by Chiesi, Inc., where he served as Executive Vice President of Operations and as President of its subsidiary, Aristos Pharmaceuticals, Inc., from July 2003 to September 2011. He received his B.A. from Moravian College in Bethlehem, PA.
Carolyn Sikes, PhD, Vice President of Clinical Affairs
Carolyn Sikes has more than 25 years of experience in medical affairs and global drug development. Prior to joining Neos in July, 2010, Dr. Sikes held various leadership roles at Pfizer Pharmaceuticals, Inc., and has worked in multiple therapeutic areas, including the development of therapeutics for depression, anxiety, post-traumatic stress disorder, Alzheimer’s disease, schizophrenia, epilepsy, pain and other central nervous system disorders. She has consulted with many small and large pharmaceutical companies in drug development, medical affairs, and compliance. She holds a PhD in Psychobiology/Neuroscience from Duke University and completed a post-doctoral fellowship in Psychoneuroendocrinology at Cornell University Medical College.